WAIKOLOA, Hawaii — At Hawaiian Eye 2022, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses data from the Phase 1 DAVIO study of EYP-1901 for wet-AMD.
“We continue to be very encouraged by these data, and we look forward to showing additional OCT and BCVA data at Angiogenesis,” Lurker said.